Ovarian Cancer Coverage from Every Angle

Niraparib in Newly Diagnosed Advanced Ovarian Cancer

By: Max J. Rosenthal
Posted: Tuesday, December 10, 2019

Treatment with the PARP inhibitor niraparib resulted in “significantly increased” durations of progression-free survival in newly diagnosed patients with advanced ovarian cancer who responded to platinum-based chemotherapy, according to the PRIMA/ENGOT-OV26/GOG-3012 trial. This finding was reported regardless of the presence or absence of homologous-recombination deficiency. Antonio González-Martín, MD, PhD, of the Clínica Universidad de Navarra, Pamplona, Spain, and colleagues published their results in The New England Journal of Medicine.

The randomized, double-blind, phase III trial included 733 patients; all had high-grade serous or endometrioid tumors classified as stage III or IV and had already responded to first-line platinum-based chemotherapy. Patients were randomly assigned daily to oral doses of either niraparib or a placebo in a 2:1 ratio in 28-day cycles for either 36 months or until disease progression.

The median progression-free survival for patients who received niraparib was 13.8 months, compared with 8.2 months for the placebo group (hazard ratio = 0.62). Among the 50.9% of patients who had tumors with homologous-recombination deficiency, the median progression-free survival was longer with niraparib (21.9 months vs. 10.4 months; hazard ratio = 0.43).

Most of the patients experienced adverse effects during the trial, and they occurred more often among the niraparib group. The most common adverse events of grade 3 or higher were anemia (31% of patients), thrombocytopenia (28.7%), and neutropenia (12.8%).

The investigators noted that most patients with advanced ovarian cancer currently “do not have an effective treatment option to substantially reduce the risk of death or progressive disease after first-line chemotherapy.” Niraparib may now offer those patients an option beyond active surveillance.

Disclosure: The study authors’ disclosure information may be found at nejm.org.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.